【摘要】 目的　探讨可溶性Fas(sFas)在大肠癌及良性病变患者中的表达及其临床意义。方法　用双抗体夹心ELISA法检测 46例大肠癌、15例息肉或腺瘤、10例溃疡性结肠炎患者血清中可溶性Fas(sFas)表达水平 ,并比较 15例大肠癌患者术前、术后sFas的变化。结果　大肠癌患者血清sFas水平 ( 16 2 8± 3 5 3ng ml)明显高于良性病变及正常人 (P <0 0 1) ,随着临床分期的上升 ,sFas水平上升明显 ;sFas与年龄、性别、肿瘤大小及组织学分级无明显相关 (P >0 0 5 )。sFas与CEA呈正相关 (P <0 0 5 )。大肠癌患者术后血清Fas水平较术前明显下降 (P <0 0 5 )。结论　sFas可以作为大肠癌一种新的肿瘤检测指标 ,与大肠癌的发生、发展密切相关更多还原

【Abstract】 Objective To detect the serum sFas levels in clolrectal cancer and analyze its clinical meaning. Methods Using double antibody sandwith ELISA, the serum sFas was tested in 46 patients with colorectal cancer, 15 patients with polyps or adenoma,10 patients with ulcerous colonitis, and in 15 patients with colorectal cancer pre and postoperation. Results The serum sFas in colorectal cancer was significantly higher than normal control and benign lesions (P<001). The sFas was lower in patients with Dukes’ A and B stages than those with Dukes’C and D stages. sFas was not related to sex, age, tumor size and histological grades, but with the CEA value (P<005). Postoperated patients showed a lower sFas than preoperation (P<005). Conclusion sFas may serve as a novel marker for colorectal cancer and may closely reflect its developemnt and progress.$$$$更多还原